Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain
This article was originally published in The Pink Sheet Daily
Executive Summary
Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.
You may also be interested in...
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.